Good afternoon :)
IPCA Laboratories Ltd

IPCA Laboratories Ltd

IPCALAB Share Price

NSE
1,911.200.58% (+11.10)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹48,487 cr, stock is ranked 216

Stock is 2.39x as volatile as Nifty

IPCALAB Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹48,487 cr, stock is ranked 216

Stock is 2.39x as volatile as Nifty

IPCALAB Performance & Key Metrics

IPCALAB Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
37.025.09
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
46.415.950.50%

IPCALAB Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
88%
Analysts have suggested that investors can buy this stock

from 17 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

IPCALAB Company Profile

Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).

IPCALAB Similar Stocks (Peers)

Compare with peers Compare with peers 

IPCALAB Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
39.76
39.76
1Y Return
15.99%
15.99%
Buy Reco %
93.55
93.55
PE Ratio
86.09
86.09
1Y Return
34.25%
34.25%
Buy Reco %
82.14
82.14
PE Ratio
29.83
29.83
1Y Return
10.08%
10.08%
Buy Reco %
62.86
62.86
PE Ratio
22.17
22.17
1Y Return
13.61%
13.61%
Buy Reco %
57.69
57.69
PE Ratio
18.88
18.88
1Y Return
12.19%
12.19%
Buy Reco %
54.55
54.55
Compare with Peers

IPCALAB Sentiment Analysis

IPCALAB Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

IPCALAB Stock Summary · June 2026

Management framed the quarter as a combination of solid top‑line growth and improving profitability, with domestic formulations at about INR 853 crore in Q4 and consolidated FY26 EBITDA margin at roughly 20.72%, above the company’s 20% target. They emphasised a disciplined, division‑level strategy that prioritises 2–3 power brands, a controlled cadence of roughly 18–20 domestic launches a year expected to add about 1–2% to domestic growth, and targeted annual price increases near 5–6%, while actively passing API cost hikes through to buyers. Management acknowledged material‑cost inflation (roughly 10–12%) and sharply higher freight and logistics costs (about +25%), which have lengthened transit times and will create a short‑term profitability drag such as in Q1 despite tight working‑capital control and elevated inventories in parts of the group. Integration actions at the acquired business—including India production shifts and elimination of overseas overheads—are expected to drive a margin recovery toward roughly 12–13% and near‑term growth, while incremental R&D and tech‑transfer spending supports institutional U.S. programs.

IPCALAB Stock Growth Drivers
IPCALAB Stock Growth Drivers
5
  • Broad-based Revenue Momentum across Markets and Segments

    The company delivered sustained top-line growth across domestic, export and U.S. channels, evidencing diversified momentum.

  • Material Margin Expansion and Profitability Outperformance

    Profitability improved meaningfully with both standalone and consolidated EBITDA margins expanding and exceeding guidance. Standalone

IPCALAB Stock Challenges
IPCALAB Stock Challenges
8
  • Sharp Decline in Institutional Sales

    The institutional segment has contracted materially, with institutional sales falling roughly 24% for the year

  • Substantial Input-Cost Inflation from Supply-Chain Disruptions

    Ongoing supply-chain disturbances and petroleum-linked pressures have driven broad input-cost inflation of roughly 10%–12%, with

IPCALAB Forecast

IPCALAB Forecasts

Price

Revenue

Earnings

IPCALAB

IPCALAB

Income

Balance Sheet

Cash Flow

IPCALAB Income Statement

IPCALAB Income Statement

Loading...

Quartermar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026
Total Revenue2,051.952,113.242,381.162,265.482,272.512,341.512,584.362,430.342,482.222,813.36
Operating & Other expensessubtract1,847.851,699.911,913.421,782.292,022.881,892.432,069.841,859.151,950.432,118.59
Depreciation/Amortizationsubtract98.1398.89100.3598.46100.12100.06103.33107.59107.14110.81
Interest & Other Itemssubtract29.3724.0522.5616.8121.5118.5119.6117.6220.2011.88
Taxes & Other Itemssubtract17.0198.15115.35119.7860.1897.30109.01119.71105.38170.19
EPS2.357.589.059.782.679.1911.1412.8613.3115.84

IPCALAB Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual report

PDF
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF

Investor Presentation

Nov 12PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

IPCALAB Stock Peers

IPCALAB Past Performance & Peer Comparison

IPCALAB Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
IPCA Laboratories Ltd42.495.09
Sun Pharmaceutical Industries Ltd39.765.440.84%
Torrent Pharmaceuticals Ltd86.0910.590.69%
Cipla Ltd29.833.350.91%

IPCALAB Stock Price Comparison

Compare IPCALAB with any stock or ETF
Compare IPCALAB with any stock or ETF
IPCALAB
Loading...

IPCALAB Holdings

IPCALAB Shareholdings

IPCALAB Promoter Holdings Trend

IPCALAB Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

IPCALAB Institutional Holdings Trend

IPCALAB Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

IPCALAB Shareholding Pattern

IPCALAB Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding44.72%31.15%6.22%10.73%7.18%

Sep 2025

Dec 2025

Mar 2026

Jun 2026

IPCALAB Shareholding History

IPCALAB Shareholding History

MarJunSepDec '25MarJun10.76%10.67%10.43%10.63%10.63%10.73%

Mutual Funds Invested in IPCALAB

Mutual Funds Invested in IPCALAB

No mutual funds holding trends are available

Top 5 Mutual Funds holding IPCA Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
6.2573%3.01%0.08%6/82 (+3)
4.4510%3.12%0.14%2/74 (0)
1.4186%2.03%0.14%7/104 (+1)

Compare 3-month MF holding change on Screener

IPCALAB Insider Trades & Bulk Stock Deals

IPCALAB Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing IPCALAB stock

smallcases containing IPCALAB stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have IPCA Laboratories Ltd

Loading...
Safe Haven Model

Safe Haven Model

Created by Windmill Capital

IPCALAB's Wtg.
9.83%
9.83%
CAGR
18.41%

IPCALAB Events

IPCALAB Events

IPCALAB Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

IPCALAB Dividend Trend

No dividend trend available

IPCALAB Upcoming Dividends

IPCALAB Upcoming Dividends

No upcoming dividends are available

IPCALAB Past Dividends

IPCALAB Past Dividends

Cash Dividend

Ex DateEx DateAug 7, 2026

Final
Final | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Aug 7, 2026

Cash Dividend

Ex DateEx DateAug 5, 2025

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Aug 5, 2025

Cash Dividend

Ex DateEx DateNov 27, 2024

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Nov 27, 2024

Cash Dividend

Ex DateEx DateAug 6, 2024

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Aug 6, 2024

Cash Dividend

Ex DateEx DateNov 22, 2023

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Nov 22, 2023

IPCALAB Stock News & Opinions

IPCALAB Stock News & Opinions

Earnings
Earnings
Ipca Laboratories Ltd consolidated sales up 16.73% on year in Q2FY2026, net profit surged by 36.65%

Ipca Laboratories Ltd share price ticked higher by 0.99% to Rs 1766.7 after the company's net profit saw a strong growth of 36.65% to Rs 422.81 crore, while revenue from operations gained 16.73% to Rs 2788.1 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, easing 4.61%. It has improved by 0.97% over last one week and advanced by 11.17% in last one month while the market capitalization of Ipca Laboratories Ltd has inched up 1.92% and 10.02% in the same period respectively. Profit before tax (PBT) of Ipca Laboratories Ltd stood at Rs 572.08 crore in Q2 FY26, surging by 73.09% year-on-year, and jumping 41.45% quarter-on-quarter. EBITDA came in at Rs 644 crore, rallying 67.88% YoY and expanding by 65.14% sequentially. Total expenses rose by 10.82% to Rs 2229.4 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 638.14 crore, posting a minor increase of 7.68% YoY, while employee benefits expense was at Rs 601.56 crore, witnessing a strong rise of 12.86% YoY. For the TTM ended FY26, revenue from operations grew marginally by 7.91% to Rs 9646.33 crore, while net profit soared by 51.28% to Rs 1191.37 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 165264% to Rs 1804.11 crore, and PBT witnessed a strong rise of 39.02% to Rs 1572.52 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1141.97 crore in FY26, as against Rs 1321.32 crore in FY25. Ipca Laboratories Ltd rallied 28.37% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.83% during the same period.

1 week agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd spurts 2.75%

Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1815.1, up 2.75% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.26% on the day, quoting at 24372.4. The Sensex is at 77881.48, down 0.11%. Ipca Laboratories Ltd has dropped around 1.37% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has dropped around 2.8% in last one month and is currently quoting at 26762.5, down 0.49% on the day. The volume in the stock stood at 2.24 lakh shares today, compared to the daily average of 2.26 lakh shares in last one month.The PE of the stock is 39.45 based on TTM earnings ending March 26.

1 week agoCapital Market - Live
Corporate
Corporate
Ipca Laboratories to announce Quarterly Result

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 August 2026.

3 weeks agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd gains for fifth session

Ipca Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1879.3, up 2.11% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 24160.1. The Sensex is at 77455.4, up 0.52%. Ipca Laboratories Ltd has risen around 21.23% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 7.92% in last one month and is currently quoting at 25907.1, up 0.64% on the day. The volume in the stock stood at 1.72 lakh shares today, compared to the daily average of 2.43 lakh shares in last one month.The PE of the stock is 40.42 based on TTM earnings ending March 26.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Corporate
Ipca Laboratories to hold AGM

Ipca Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 13 August 2026.

1 month agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd spurts 2.44%

Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1831.5, up 2.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.04% on the day, quoting at 24216.7. The Sensex is at 77693.16, up 0.16%. Ipca Laboratories Ltd has risen around 16.23% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 5.67% in last one month and is currently quoting at 25674.1, down 0.32% on the day. The volume in the stock stood at 2.25 lakh shares today, compared to the daily average of 2.31 lakh shares in last one month.The PE of the stock is 39.27 based on TTM earnings ending March 26.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Corporate
Ipca Laboratories board approves scheme of amalgamation

The board of Ipca Laboratories at its meeting held on 26 June 2026 has approved the scheme of amalgamation of Krebs Biochemicals & Industries (Transferor Company) with the company (Transferee Company) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

1 month agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd spurts 0.16%, up for fifth straight session

Ipca Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 1627.6, up 0.16% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.7% on the day, quoting at 23991.35. The Sensex is at 76862.12, up 0.87%. Ipca Laboratories Ltd has gained around 3.6% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has gained around 1.73% in last one month and is currently quoting at 24989.95, up 0.45% on the day. The volume in the stock stood at 51017 shares today, compared to the daily average of 2.5 lakh shares in last one month.The PE of the stock is 35.66 based on TTM earnings ending March 26.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd eases for fifth straight session

Ipca Laboratories Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1575.6, down 0.47% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 1.17% on the day, quoting at 23899.05. The Sensex is at 76440.61, up 1.21%.Ipca Laboratories Ltd has eased around 4.29% in last one month.Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has eased around 2.12% in last one month and is currently quoting at 24380.05, down 0.58% on the day. The volume in the stock stood at 77999 shares today, compared to the daily average of 3.04 lakh shares in last one month.The PE of the stock is 34.84 based on TTM earnings ending March 26.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd soars 0.79%, rises for fifth straight session

Ipca Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1654.8, up 0.79% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.55% on the day, quoting at 23237.85. The Sensex is at 73854.65, down 0.52%. Ipca Laboratories Ltd has risen around 7.8% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 0.72% in last one month and is currently quoting at 24248.05, up 0.4% on the day. The volume in the stock stood at 6.88 lakh shares today, compared to the daily average of 3.84 lakh shares in last one month.The PE of the stock is 36.1 based on TTM earnings ending March 26.Powered by Capital Market - Live

2 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of IPCA Laboratories Ltd (IPCALAB) today?

    The share price of IPCALAB as on 21st August 2026 is ₹1911.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on IPCA Laboratories Ltd (IPCALAB) share?

    The past returns of IPCA Laboratories Ltd (IPCALAB) share are
    • Past 1 week: 7.73%
    • Past 1 month: 4.19%
    • Past 3 months: 16.75%
    • Past 6 months: 29.69%
    • Past 1 year: 40.62%
    • Past 3 years: 115.47%
    • Past 5 years: 49.03%

  3. What are the peers or stocks similar to IPCA Laboratories Ltd (IPCALAB)?
  4. What is the market cap of IPCA Laboratories Ltd (IPCALAB) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of IPCA Laboratories Ltd (IPCALAB) is ₹48487.95 Cr as of 21st August 2026.

  5. What is the 52 week high and low of IPCA Laboratories Ltd (IPCALAB) share?

    The 52-week high of IPCA Laboratories Ltd (IPCALAB) is ₹1945.10 and the 52-week low is ₹1251.60.

  6. What is the PE and PB ratio of IPCA Laboratories Ltd (IPCALAB) stock?

    The P/E (price-to-earnings) ratio of IPCA Laboratories Ltd (IPCALAB) is 42.49. The P/B (price-to-book) ratio is 5.09.

  7. Which sector does IPCA Laboratories Ltd (IPCALAB) belong to?

    IPCA Laboratories Ltd (IPCALAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy IPCA Laboratories Ltd (IPCALAB) shares?

    You can directly buy IPCA Laboratories Ltd (IPCALAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.